Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain
Grünenthal, a global leader in pain management, and Mesoblast Limited, a world leader in allogeneic cellular medicines for inflammatory diseases, announced that they have entered into a strategic partnership to develop and commercialise MPC-06-ID, a Phase III allogeneic cell therapy